These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

848 related articles for article (PubMed ID: 32416679)

  • 1. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
    Sternberg A; McKee DL; Naujokat C
    Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
    Vardhan S; Sahoo SK
    Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
    Choudhary S; Silakari O
    Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
    Choudhary S; Malik YS; Tomar S
    Front Immunol; 2020; 11():1664. PubMed ID: 32754161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19.
    Poduri R; Joshi G; Jagadeesh G
    Cell Signal; 2020 Oct; 74():109721. PubMed ID: 32711111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2.
    Zhang Y; Kutateladze TG
    Nat Commun; 2020 Jun; 11(1):2920. PubMed ID: 32523109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
    Fu L; Ye F; Feng Y; Yu F; Wang Q; Wu Y; Zhao C; Sun H; Huang B; Niu P; Song H; Shi Y; Li X; Tan W; Qi J; Gao GF
    Nat Commun; 2020 Sep; 11(1):4417. PubMed ID: 32887884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
    Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J
    Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
    Giovane RA; Rezai S; Cleland E; Henderson CE
    Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alkamides and Piperamides as Potential Antivirals against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Gutierrez-Villagomez JM; Campos-García T; Molina-Torres J; López MG; Vázquez-Martínez J
    J Phys Chem Lett; 2020 Oct; 11(19):8008-8016. PubMed ID: 32840378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
    Martorana A; Gentile C; Lauria A
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp).
    da Silva FMA; da Silva KPA; de Oliveira LPM; Costa EV; Koolen HH; Pinheiro MLB; de Souza AQL; de Souza ADL
    Mem Inst Oswaldo Cruz; 2020; 115():e200207. PubMed ID: 33027419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H
    Yang G
    Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
    Gurard-Levin ZA; Liu C; Jekle A; Jaisinghani R; Ren S; Vandyck K; Jochmans D; Leyssen P; Neyts J; Blatt LM; Beigelman L; Symons JA; Raboisson P; Scholle MD; Deval J
    Antiviral Res; 2020 Oct; 182():104924. PubMed ID: 32896566
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
    OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Targets in the Chemotherapy of Coronavirus Infection.
    Zhirnov OP
    Biochemistry (Mosc); 2020 May; 85(5):523-530. PubMed ID: 32571182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking.
    Joshi T; Joshi T; Sharma P; Mathpal S; Pundir H; Bhatt V; Chandra S
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4529-4536. PubMed ID: 32373991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.